PERSEUS --- 2D Material-Based Multiple Oncotherapy Against Metastatic Disease Using a Radically New Computed Tomography Approach

PERSEUS --- 使用全新的计算机断层扫描方法针对转移性疾病进行基于 2D 材料的多重肿瘤治疗

• 批准号: 10073017
• 金额: $ 28.3万
• 依托单位: QED FILM & STAGE PRODUCTIONS LTD
• 依托单位国家: 英国
• 项目类别: EU-Funded
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10073017
• 关键词: PERSEUS; 2D; Material; Based; Multiple

PERSEUS is developing a novel nanotechnology-based cancer treatment for deep-seated, clinically unmanageable, drug-resistant, and metastatic tumours. Practical use of nanotechnology in clinical cancer care is still in its infancy, its full potential yet to be realised. The treatment is based on a novel nano-system (NS) made of multifunctional 2D-layered nanocrystals. The NS enables, under activation by computed tomography (CT) X-rays, an effective multimodal therapy with minimal or no adverse effects. This novel paradigm uses CT X-rays not to eradicate cancer, but to trigger and to image the NS that locally activates non-mutagenic oncolytic mechanisms. The therapeutic effect is due to the conversion of low energy X-rays from CT scanners into heat, reactive oxygen species, and radiosensitising agents. X-ray irradiation can also induce immunogenic cell death with the exposure or release of neo-antigens to trigger an anti-cancer immune response. The use of X-rays makes it possible to reach deep-seated tumours that are inaccessible by visible or near-infrared light-based therapies. In other words, CT is the spark that lights the match. This is a radical vision for an ambitious and high-risk project. The project targets a range of cancer types, including metastatic triple negative breast cancer, hepatocellular carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma. The NS is biocompatible and also totally inactive in the absence of CT radiation, i.e. the NS becomes active only where the CT beam is delivered, hence minimising side effects at distal sites. The therapy is agnostic to the type of cancer and to gender incidence because it doesn't affect the body biochemistry. This is a second change of paradigm. The vision behind PERSEUS is pursued by a multidisciplinary team composed of physicists, chemists, chemical engineers, biologists, physicians, pharmacologists, and radiologists, working together to develop an innovative nanotechnological approach to address unmet clinical needs.

PERSEUS 正在开发一种基于纳米技术的新型癌症治疗方法，用于治疗深部、临床上难以控制、耐药和转移性肿瘤。纳米技术在临床癌症护理中的实际应用仍处于起步阶段，其全部潜力尚未得到充分发挥。该治疗基于由多功能二维层状纳米晶体制成的新型纳米系统（NS）。 NS 在计算机断层扫描 (CT) X 射线的激活下能够实现有效的多模式治疗，且副作用最小或没有副作用。这种新颖的范例使用 CT X 射线不是为了根除癌症，而是为了触发和成像局部激活非诱变溶瘤机制的 NS。治疗效果是由于 CT 扫描仪发出的低能 X 射线转化为热量、活性氧和放射增敏剂。 X 射线照射还可以通过暴露或释放新抗原来诱导免疫原性细胞死亡，从而触发抗癌免疫反应。 X 射线的使用使得能够到达可见光或近红外光疗法无法到达的深层肿瘤。换句话说，CT是点燃火柴的火花。这是一个雄心勃勃且高风险项目的激进愿景。该项目针对一系列癌症类型，包括转移性三阴性乳腺癌、肝细胞癌、结直肠癌、胰腺导管腺癌。 NS 具有生物相容性，并且在没有 CT 辐射的情况下也完全不活跃，即 NS 仅在传输 CT 束时才变得活跃，从而最大限度地减少远端部位的副作用。该疗法与癌症类型和性别发病率无关，因为它不影响身体的生物化学。这是范式的第二次改变。 PERSEUS 背后的愿景是由物理学家、化学家、化学工程师、生物学家、医生、药理学家和放射学家组成的多学科团队共同追求的，他们共同开发一种创新的纳米技术方法来解决未满足的临床需求。